Eight-week glecaprevir/pibrentasvir in Canadian hepatitis C virus-infected, treatment-naïve, compensated cirrhotic people: CREST study

Aim: Evaluation of the real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir (G/P) in treatment-naive Canadian individuals with hepatitis C and compensated cirrhosis. Patients & methods: Analysis of Canadian people enrolled in the CREST study. Primary end point was sustained virologic response at posttreatment Week 12 (SVR12) rates; safety end points were also assessed. Results: Fifty-three individuals received ≥1 dose of G/P. In the modified analysis set (MAS; which excluded those who discontinued G/P [n = 1] or with missing SVR12 data [n = 12]), 98% (39/40) achieved SVR12; 1 person experienced virologic failure. No individuals experienced or discontinued treatment due to a serious adverse event. Conclusion: In this real-world Canadian cohort, 8-week G/P was well tolerated, with SVR12 rates similar to those in clinical trials.